RT Journal Article
T1 Impact of prevalence ratios of chondroitin sulfate (CS)- 4 and -6 isomers derived from marine sources in cell proliferation and chondrogenic differentiation processes
A1 Lopez Senra, Estefanía
A1 Casal Beiroa, Paula
A1 López Álvarez, Miriam
A1 Serra Rodríguez, Julia Asunción
A1 González Fernández, Pío Manuel
A1 Valcarcel, Jesús
A1 Vázquez, José Antonio
A1 Burguera, Elena F.
A1 Blanco, Francisco J.
A1 Magalhães, Joana
K1 22 Física
K1 2407.01 Cultivo Celular
K1 3312 Tecnología de Materiales
AB Osteoarthritis is the most prevalent rheumatic disease. During disease progression, differences have been described in the prevalence of chondroitin sulfate (CS) isomers. Marine derived-CS present a higher proportion of the 6S isomer, offering therapeutic potential. Accordingly, we evaluated the effect of exogenous supplementation of CS, derived from the small spotted catshark (Scyliorhinus canicula), blue shark (Prionace glauca), thornback skate (Raja clavata) and bovine CS (reference), on the proliferation of osteochondral cell lines (MG-63 and T/C-28a2) and the chondrogenic differentiation of mesenchymal stromal cells (MSCs). MG-G3 proliferation was comparable between R. clavata (CS-6 intermediate ratio) and bovine CS (CS-4 enrichment), for concentrations below 0.5 mg/mL, defined as a toxicity threshold. T/C-28a2 proliferation was significantly improved by intermediate ratios of CS-6 and -4 isomers (S. canicula and R. clavata). A dose-dependent response was observed for S. canicula (200 µg/mL vs 50 and 10 µg/mL) and bovine CS (200 and 100 µg/mL vs 10 µg/mL). CS sulfation patterns discretely affected MSCs chondrogenesis; even though S. canicula and R. clavata CS up-regulated chondrogenic markers expression (aggrecan and collagen type II) these were not statistically significant. We demonstrate that intermediate values of CS-4 and -6 isomers improve cell proliferation and offer potential for chondrogenic promotion, although more studies are needed to elucidate its mechanism of action.
PB Marine Drugs
SN 16603397
YR 2020
FD 2020-01-31
LK http://hdl.handle.net/11093/2021
UL http://hdl.handle.net/11093/2021
LA eng
NO Marine Drugs, 18(2): 94 (2020)
NO Xunta de Galicia | Ref. AGRUP 2015/05 (CICA-INIBIC)
DS Investigo
RD 12-sep-2024